Intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria. research hub

A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab, versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE).

This study looks at new ways to treat a type of liver cancer that has spread. It compares two treatments: one using regorafenib and pembrolizumab given through the body, and another using targeted treatments like TACE or TARE directly in the liver. The main goal is to see which treatment works best to stop the cancer from growing.